Deal includes $80 million upfront payment, with total potential value up to $1.04 billion plus royalties ADEL grants exclusive worldwide rights for acetylated tau-targeting antibody 'ADEL-Y01' to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results